Femtogenix Presents Data on Reduced Potency ADC Payload
UK-based Femtogenix announced data demonstrating the efficacy and favorable toxicity profile of a reduced potency analog from its Pyridinobenzodiazepine ADC payload platform.
Femtogenix, a biotechnology company based in the UK, has presented new data on its next-generation DNA-interactive Antibody Drug Conjugate (ADC) payload platform. The company announced that a reduced potency analog from its Pyridinobenzodiazepine (PDD) ADC payload platform demonstrated potent efficacy and a favorable toxicity profile in solid tumor models.
The presented data indicated that Femtogenix's reduced potency payload exhibited a favorable toxicity profile in rats, demonstrating potent in vivo efficacy (MED < 1 mg/kg) and improved tolerability (MTD of 40 mg/kg) in solid tumor models when conjugated to antibodies. The payload's toxicity profile and wide therapeutic window allow for increased drug-antibody ratios (DAR) beyond the traditional limit of two.
The findings were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston. The Antibody Drug Conjugates market is projected to approach $15 billion by 2030, with auristatin currently being the most frequently used payload in clinical pipelines, followed by maytansinoid and PBD.
Femtogenix continues to research and develop its ADC payloads with the aim of improving treatment outcomes for patients with various cancers.